X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CADILA HEALTHCARE NATCO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 16.7 19.5 85.8% View Chart
P/BV x 18.0 4.6 390.1% View Chart
Dividend Yield % 0.6 0.9 71.6%  

Financials

 NATCO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
CADILA HEALTHCARE
Mar-18
NATCO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs877558 157.2%   
Low Rs424362 117.2%   
Sales per share (Unadj.) Rs223.4116.3 192.1%  
Earnings per share (Unadj.) Rs31.117.9 173.9%  
Cash flow per share (Unadj.) Rs40.323.1 174.1%  
Dividends per share (Unadj.) Rs5.003.50 142.9%  
Dividend yield (eoy) %0.80.8 101.0%  
Book value per share (Unadj.) Rs219.585.4 257.0%  
Shares outstanding (eoy) m33.071,023.74 3.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.0 73.6%   
Avg P/E ratio x20.925.7 81.3%  
P/CF ratio (eoy) x16.119.9 81.2%  
Price / Book Value ratio x3.05.4 55.0%  
Dividend payout %16.119.6 82.2%   
Avg Mkt Cap Rs m21,504470,664 4.6%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m1,12818,545 6.1%   
Avg. sales/employee Rs ThNM10,072.7-  
Avg. wages/employee Rs ThNM1,569.1-  
Avg. net profit/employee Rs ThNM1,547.7-  
INCOME DATA
Net Sales Rs m7,389119,049 6.2%  
Other income Rs m1671,132 14.8%   
Total revenues Rs m7,556120,181 6.3%   
Gross profit Rs m1,79328,475 6.3%  
Depreciation Rs m3045,388 5.6%   
Interest Rs m366911 40.2%   
Profit before tax Rs m1,29023,308 5.5%   
Minority Interest Rs m46628 7.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3095,644 5.5%   
Profit after tax Rs m1,02718,292 5.6%  
Gross profit margin %24.323.9 101.5%  
Effective tax rate %23.924.2 98.8%   
Net profit margin %13.915.4 90.5%  
BALANCE SHEET DATA
Current assets Rs m3,68182,005 4.5%   
Current liabilities Rs m3,12360,720 5.1%   
Net working cap to sales %7.617.9 42.3%  
Current ratio x1.21.4 87.3%  
Inventory Days Days8973 122.3%  
Debtors Days Days5998 59.7%  
Net fixed assets Rs m7,68583,703 9.2%   
Share capital Rs m3311,024 32.3%   
"Free" reserves Rs m6,67086,421 7.7%   
Net worth Rs m7,25987,445 8.3%   
Long term debt Rs m95525,551 3.7%   
Total assets Rs m11,957180,653 6.6%  
Interest coverage x4.526.6 17.0%   
Debt to equity ratio x0.10.3 45.0%  
Sales to assets ratio x0.60.7 93.8%   
Return on assets %11.710.6 109.6%  
Return on equity %14.220.9 67.7%  
Return on capital %20.722.0 94.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44542,683 8.1%   
Fx outflow Rs m70311,242 6.3%   
Net fx Rs m2,74331,441 8.7%   
CASH FLOW
From Operations Rs m1,4409,193 15.7%  
From Investments Rs m-1,089-9,737 11.2%  
From Financial Activity Rs m-353515 -68.5%  
Net Cashflow Rs m-1-29 5.1%  

Share Holding

Indian Promoters % 52.0 74.8 69.6%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 8.3 94.5%  
FIIs % 16.6 5.9 281.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 11.0 236.4%  
Shareholders   25,395 44,069 57.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - STERLING BIOTECH COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS